Cantargia: New Positive Readout in NSCLC
Redeye comments on the new readout in non-small cell lung cancer presented at ASCO 2023. In particular, the complete response with nadunolimab as monotherapy is highly encouraging.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock